181 related articles for article (PubMed ID: 37377735)
1. Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma.
Battaglia AM; Sacco A; Aversa I; Santamaria G; Palmieri C; Botta C; De Stefano R; Bitetto M; Petriaggi L; Giorgio E; Faniello CM; Costanzo F; Biamonte F
Front Cell Dev Biol; 2023; 11():1208485. PubMed ID: 37377735
[No Abstract] [Full Text] [Related]
2. Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells.
Tong L; Shan M; Zou W; Liu X; Felsher DW; Wang J
Front Oncol; 2022; 12():904969. PubMed ID: 35978822
[TBL] [Abstract][Full Text] [Related]
3. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
4. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
Yang P; He S; Ye L; Weng H
Int Arch Allergy Immunol; 2024 May; ():1-11. PubMed ID: 38781935
[TBL] [Abstract][Full Text] [Related]
5. Silencing of Perilipin 3 Inhibits Lung Adenocarcinoma Cell Immune Resistance by Regulating the Transcription of PD-L1 Through c-Myc.
Men X; Zhu W
Immunol Invest; 2023 Nov; 52(7):815-831. PubMed ID: 37578465
[TBL] [Abstract][Full Text] [Related]
6. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
[TBL] [Abstract][Full Text] [Related]
7. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians.
Bie F; Tian H; Sun N; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhou B; Gao S
Clin Epigenetics; 2021 Dec; 13(1):229. PubMed ID: 34933667
[TBL] [Abstract][Full Text] [Related]
9. BIRC5 Modulates PD-L1 Expression and Immune Infiltration in Lung Adenocarcinoma.
Ma T; Gu J; Wen H; Xu F; Ge D
J Cancer; 2022; 13(10):3140-3150. PubMed ID: 36046648
[No Abstract] [Full Text] [Related]
10. An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
Wang Q; Xie B; Sun J; Li Z; Xiao D; Tao Y; She X
J Cancer; 2024; 15(6):1687-1700. PubMed ID: 38370388
[No Abstract] [Full Text] [Related]
11. Characteristics of the immune microenvironment associated with RRM2 expression and its application to PD-L1/PD-1 inhibitors in lung adenocarcinoma.
Lee SK; Hwang Y; Han JH; Haam S; Lee HW; Koh YW
Am J Cancer Res; 2023; 13(11):5443-5454. PubMed ID: 38058821
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
13. Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
Li L; Yang L; Cheng S; Fan Z; Shen Z; Xue W; Zheng Y; Li F; Wang D; Zhang K; Lian J; Wang D; Zhu Z; Zhao J; Zhang Y
Mol Cancer; 2019 Jun; 18(1):108. PubMed ID: 31221150
[TBL] [Abstract][Full Text] [Related]
14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
15. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
[TBL] [Abstract][Full Text] [Related]
16. Association of long noncoding RNA MALAT1 with the radiosensitivity of lung adenocarcinoma cells via the miR-140/PD-L1 axis.
Li S; Xie Y; Zhou W; Zhou Q; Tao D; Yang H; Mao K; Li S; Lei J; Wu Y; Wang Y
Heliyon; 2023 Jun; 9(6):e16868. PubMed ID: 37332979
[TBL] [Abstract][Full Text] [Related]
17. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
Zheng JQ; Lin CH; Lee HH; Chang WM; Li LJ; Su CY; Lee KY; Chiu HW; Lin YF
Cancer Sci; 2023 Jan; 114(1):306-320. PubMed ID: 36104978
[TBL] [Abstract][Full Text] [Related]
18. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
Zhu J; Li Y; Lv X
Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
[TBL] [Abstract][Full Text] [Related]
19. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
[TBL] [Abstract][Full Text] [Related]
20. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
